Edition:
United Kingdom

Nice Ltd (NICE.OQ)

NICE.OQ on NASDAQ Stock Exchange Global Select Market

96.96USD
23 Feb 2018
Change (% chg)

$1.64 (+1.72%)
Prev Close
$95.32
Open
$96.04
Day's High
$96.99
Day's Low
$95.12
Volume
34,787
Avg. Vol
50,028
52-wk High
$96.99
52-wk Low
$65.74

Chart for

About

NICE Ltd., formerly NICE-Systems Ltd., is a global enterprise software provider. The Company's segments include Customer Interactions Solutions, and Financial Crime and Compliance Solutions. The Customer Interactions Solutions segment provides data driven insights that enable businesses to deliver personalized experience to... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $4,856.07
Shares Outstanding(Mil.): 60.35
Dividend: 0.16
Yield (%): 0.79

Financials

  Industry Sector
P/E (TTM): -- 32.63 16.60
EPS (TTM): -- -- --
ROI: -- 11.84 10.66
ROE: -- 13.87 14.30

BRIEF-NICE Q4 Earnings Per Share $1.27

* NICE REPORTS STRONG FINISH TO 2017 WITH 31% GROWTH IN ANNUAL REVENUE AND 14% GROWTH IN ANNUAL EPS

15 Feb 2018

Israel's Nice Q4 profit tops estimates, sees strong 2018

TEL AVIV, Feb 15 Israeli software provider Nice posted better-than-expected fourth-quarter profit on record revenue and forecast strong growth in 2018, boosted by its analytic and cloud tools.

15 Feb 2018

Israel's Nice tops Q3 estimates, tweaks 2017 profit forecast

JERUSALEM, Nov 2 Israeli software provider Nice narrowed the range of its 2017 earnings estimate after topping third-quarter forecasts boosted by higher revenue in its omni-channel, cloud, analytics and artificial intelligence businesses.

02 Nov 2017

BRIEF-Nice Ltd reports Q3 earnings per share of $0.42

* ‍Q3 2017 total revenues increased 36.1% to $322.8 million compared to $237.2 million for Q3 of 2016​

02 Nov 2017

UK's NICE gives Roche drug green light for bladder cancer

LONDON Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

01 Nov 2017

UK's NICE gives Roche drug green light for bladder cancer

LONDON Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

01 Nov 2017

UK's NICE gives Roche drug green light for bladder cancer

LONDON, Nov 1 Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

01 Nov 2017

BRIEF-Migdal Insurance & Financial Holdings reports 4.95 pct passive stake ​ in Nice as of Oct 26

* Migdal Insurance & Financial Holdings Ltd reports 4.95 percent passive stake ​ in Nice Ltd as of Oct 26 - SEC filing Source text: (http://bit.ly/2lxaLhu) Further company coverage:

31 Oct 2017

Earnings vs. Estimates